NASDAQ:ALGS | Free Cash Flow | Aligos Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$23.13M
2025-12-31-$21.75M
2025-03-31-$20.91M
2024-12-31-$18.4M
2024-03-31-$22.75M
2023-12-31-$22.66M
2023-03-31-$22.39M$7,000.00-$22.39M
2022-12-31-$16.78M$91,000.00-$16.87M
2022-03-31-$20.43M$515,000.00-$20.95M
2021-12-31-$37.48M$336,000.00-$37.82M
2021-03-31-$29.8M$307,000.00-$30.1M
2020-12-31-$19.68M$61,000.00-$19.75M
2020-03-31-$20.32M$1.09M-$21.41M
2019-12-31-$15.02M$721,000.00-$15.74M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$82.5M
2024-12-31-$80.74M$130,000.00-$80.87M
2023-12-31-$79M$19,000.00-$79.02M
2022-12-31-$79.39M$943,000.00-$80.33M
2021-12-31-$115.66M$892,000.00-$116.55M
2020-12-31-$74.26M$2.06M-$76.33M
2019-12-31-$46.77M$2.79M-$49.55M